Antinuclear antibodies (ANA) are a group of autoantibodies produced by a person's immune system when it fails to adequately distinguish between "self" and "nonself." The ANA testing detects these autoantibodies in the blood.
Market Analysis and Insights: Global and United States Anti-nuclear Antibody (ANA) Testing Market
This report focuses on global and United States Anti-nuclear Antibody (ANA) Testing market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Anti-nuclear Antibody (ANA) Testing market size is estimated to be worth US$ 1255.5 million in 2022 and is forecast to a readjusted size of US$ 1794.2 million by 2028 with a CAGR of 6.1% during the review period. Fully considering the economic change by this health crisis, by Type, Indirect Immunofluorescence accounting for % of the Anti-nuclear Antibody (ANA) Testing global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Hospital was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
In United States the Anti-nuclear Antibody (ANA) Testing market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period.
Global Anti-nuclear Antibody (ANA) Testing Scope and Market Size
Anti-nuclear Antibody (ANA) Testing market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Anti-nuclear Antibody (ANA) Testing market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Anti-nuclear Antibody (ANA) Testing market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Indirect Immunofluorescence
Enzyme-linked Immunosorbent Assay (ELISA)
Other
Segment by Application
Hospital
Clinic
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Abcam
Antibodies
Bio-Rad Laboratories
Alere
Erba Diagnostics
MBL International
Merck
Indur Services
Trinity Biotech
Thermo Fisher Scientific
Zeus Scientific